Invenra

Founded in 2011, Invenra has developed a robust technology platform centered on its B-Body® bispecific antibody scaffold, which is engineered for high yield, stability, and simplified manufacturing. The company is advancing a pipeline of novel bi- and multi-specific candidates, initially focused on oncology, and has established strategic partnerships, such as with Twist Bioscience, to expand the reach of its platform. As a private company, Invenra combines internal R&D with a service-based business model, positioning itself as a key player in the next generation of antibody therapeutics.

The B-Body® Platform is a proprietary, human IgG-like bispecific antibody scaffold engineered for high yield (6-11 g/L), proper chain assembly, simple purification, and full CMC compatibility. It enables the discovery and development of bispecific and trispecific antibodies with high solubility, stability, and subcutaneous administration potential.

Invenra competes in the crowded bispecific antibody platform space with companies like Amgen (BiTE), Genmab (DuoBody), and Regeneron. Its key differentiators are the exceptionally high yield and integrated CMC compatibility of its B-Body® scaffold, which aims to reduce development timelines and manufacturing costs for partners and its own programs.